Navigation Links
NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Date:12/14/2007

SOPHIA ANTIPOLIS, France, Dec. 14 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced it has successfully completed the enrollment of 1020 patients in the 302 pivotal phase 3 study for naproxcinod, in-line with projections. Naproxcinod is the Company's lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class. The 302 study is designed to assess naproxcinod's efficacy for treating the signs and symptoms of osteoarthritis and provide additional blood pressure data, which is a key factor for differentiating naproxcinod from existing anti-inflammatory treatments. Efficacy results from this study are anticipated in the third quarter of 2008.

The 302 study represents the largest of the three pivotal phase 3 trials for naproxcinod (the 301, 302 and 303 studies). The 301 study is complete and results were recently presented at the 71st annual meeting of the American College of Rheumatology (ACR), which showed that naproxcinod met all three co-primary efficacy endpoints and demonstrated a similar effect on systolic blood pressure to placebo and a reduction compared to naproxen, a commonly used anti-inflammatory agent. The third and final study (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is well underway, following its initiation in June 2007. Current timelines are that the 303 study should complete enrollment in the second quarter of 2008, with results expected by the end of 2008. NicOx now anticipates the filing of a New Drug Application (NDA) for naproxcinod with the US Food and Drug Administration (FDA) in mid-2009.

"The 302 study is the largest and longest duration trial in our program for naproxcinod and our clinical team has proved its effectiveness in successfully recruiting the targeted number of patients in-line with projected timelines," said Pascal Pfister, Chief Scientific Officer of NicOx. "The 302 study will p
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
(Date:8/29/2014)... PASO ROBLES, Calif. , Aug. 29, 2014 /PRNewswire/ ... launch of its new website design . The ... an overhaul that showcases the company,s new services and ... By implementing a new streamlined design, viewers can ... deliver metrics for health care practices and create a ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ –  ... PHG AEX: PHIA) today announced ... Society of Cardiology (ESC) Congress 2014 ... range of its cardiology solutions serving clinicians and ... prevention and diagnosis, to treatment, ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... FRANKLIN LAKES, N.J., Nov. 3, 2010 BD (Becton, Dickinson ... medical technology company, today reported quarterly revenues of $1.873 billion ... an increase of 1.0 percent from the prior-year period, or ... For the full fiscal year ended September 30, 2010, BD ...
... EATONTOWN, N.J., Nov. 3, 2010 Osteotech, Inc. (Nasdaq: ... field of biologic products for regenerative healing, announced today ... has been selected to receive the Research and Development ... Award in the medical category.  Osteotech was chosen from ...
Cached Medicine Technology:BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 2BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 3BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 4BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 5BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 6BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 7BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 8BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 9BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 10BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 11BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 12BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 13BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 14BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 15BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 16BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 17Osteotech's Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council 2Osteotech's Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council 3
(Date:8/29/2014)... have been hospitalized for a burn as a child experience ... to new research at the University of Adelaide . ... been conducted by the University,s Centre for Traumatic Stress Studies. ... some form of mental illness and 30% suffered depression at ... in the journal Burns , also found ...
(Date:8/29/2014)... disease outbreaks across the Arabian Peninsula and spread to ... the lives of several hundred people since its discovery ... puzzled over how easily the pathogen spreads from human ... virologists from the University of Bonn have now come ... of human transmission is low. Still, a third of ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... HealthDay Reporter , THURSDAY, Aug. 28, ... days of the Ebola outbreak in West Africa has given ... Researchers report in the Aug. 28 online issue of ... The Ebola strains responsible for the current outbreak ... first recorded outbreak of Ebola in central Africa in 1976. ...
(Date:8/29/2014)... (HealthDay News) -- The way that parents respond to ... a new study suggests. Over six months, researchers ... during free play. The sessions were 30 minutes long ... months old at the start of the study. ... infants began to form complex sounds. The babies whose ...
Breaking Medicine News(10 mins):Health News:Intervention needed for survivors of childhood burns 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Gene Research Yields Insights Into Ebola Virus 2Health News:Gene Research Yields Insights Into Ebola Virus 3Health News:Encouraging Your Baby's Babbling May Speed Language Development 2
... Center researchers have discovered that bortezomib, a promising cancer ... tumor cells by revving up the action of a ... suggest a novel treatment strategy that might someday prove ... into overdrive, so that they self-destruct. , The U-M ...
... 20 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials ... drug delivery products, today,announced that President and CEO Robert ... Fourth Annual Healthcare Conference at the Palace,Hotel in New ... p.m. EST. Lazard Capital Markets will host a ...
... Again: MAGNETOM Verio Brings High-, Resolution MRI ... Delivers the Newest Technology ... 20 Siemens Medical,Solutions (http://www.usa.siemens.com/medical ) is once ... services with the introduction of two,new magnetic resonance imaging ...
... KILLING US with cancers of the prostate, ... kidney, bone, etc? by Randall Dale Chipkar, MISSISSAUGA, ... motorcyclists to protect themselves. In his just released book,MOTORCYCLE ... He asks, "Are unsuspecting riders at risk for cancer,development ...
... protein albumin suggests worsening coronary artery disease, study finds ... small amount of a protein called albumin in the ... their risk of cardiovascular death, say U.S. researchers. , ... age 50 and older, with stable coronary artery disease ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac,surgery products ... the,19th Annual Piper Jaffray Health Care Conference at the ... 2007, at 8:30 a.m. Eastern Time.,Michael Dale, President and ... Company,s historical financial results and overall business strategy. ...
Cached Medicine News:Health News:Cancer drug works by overactivating cancer gene 2Health News:Cancer drug works by overactivating cancer gene 3Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 2Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 3Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 4Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 5Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 6Health News:New Book Links Motorcycle Radiation to Cancer Risk 2Health News:Urine Test Results Can Point to Heart Dangers 2Health News:ATS Medical to Present at the 19th Annual Piper Jaffray Health Care Conference 2
Ad-Techs Epidural Peg Electrodes feature a silicone-insulated titanium contact. To accommodate varying skull thicknesses, the post lengths range in length from 4 to 16 mm. The connecting lead wires e...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
... provide you with an alternative method for ... proven design as Ad-Techs Spencer Probe Depth ... an introducing needle instead of a stylet. ... 3 to 6 platinum recording contacts, 5.0 ...
... is designed for laboratories looking for time ... in system operation in terms of easy ... calibration and on-board stability., ,URISYS 2400 ... enhanced walk-away capability for medium to high ...
Medicine Products: